Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by XOMA Corporation
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Royalty to Present at Upcoming Investor Conferences in September
September 04, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
KNTE
XOMA
XOMAO
XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
KNTE
XOMA
XOMAO
XOMAP
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
KNTE
XOMA
XOMAO
XOMAP
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Announces Stock Repurchase Program of up to $50 Million
January 02, 2024
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
OWL
XOMA
XOMAO
XOMAP
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 07, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
September 25, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
August 08, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Added to the Russell 2000® and Russell 3000® Indexes
June 23, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
June 22, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2023
From
XOMA Corporation
Via
GlobeNewswire
Tickers
XOMA
XOMAO
XOMAP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit